The CMPSR continues to provide a resource for high quality collection and analysis of pharmacokinetic specimens. However, the CMPSR has greatly expanded to include collection, processing and analysis of clinical specimens for translational/correlative and pharmacodynamic studies associated with the Center's clinical trials program. Additional objectives of the CMPSR are to: 1) Provide a resource for high-quality collection, processing and analysis of clinical specimens for pharmacokinetic and correlative studies;2) Develop translational components for investigator-initiated clinical trials;and 3) Identify and validate biomarkers and molecular signatures that are predictive of response to therapy and investigate drug activity, pharmacodynamic responses and mechanisms of acquired or innate resistance. Further, the CMPSR provides UC Davis clinical investigators a comprehensive resource for clinical trial protocol development, including standardized and/or trial-specific language for specimen collection, and development of correlative study scientific components. It also provides services for preclinical modeling and biologic investigations of novel agents and therapeutic combinations that can serve as rationale for study development. Resource personnel work closely with the CTSU and clinical trial investigators to incorporate comprehensive and meaningful correlative and pharmacokinetic components into each trial. Users of the CMPSR are primarily UC Davis Cancer Center clinical investigators developing clinical trials. The CMPSR involvement in a clinical trial may range from the collection and shipping of UCD patient blood specimens enrolled on a cooperative group study, to broader roles including development and implementation of specialized specimen collection procedures and novel assays, comprehensive molecular correlative analysis of trial specimens and preclinical in vitro or in vivo modeling to generate drug mechanism hypotheses that can be tested in the clinic. These efforts often include significant CMPSR input during trial protocol development. The CMPSR also services as a bridge between clinical investigators with other Shared Resources.

Public Health Relevance

This resource handles biological specimens used to understand how cancer therapies work, how cancers can be detected, how the body processes drugs, and how various combinations of therapies can be more or less effective. The specimens and analytical studies are carried out in conjunction, for the most part, with cancer clinical trials. Its results are important to improving options for treating different types of cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-12
Application #
8743648
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
12
Fiscal Year
2014
Total Cost
$152,393
Indirect Cost
$53,106
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331
Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182
Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529
Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162
Tepper, Clifford G; Dang, Julie H T; Stewart, Susan L et al. (2018) High frequency of the PNPLA3 rs738409 [G] single-nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease. Cancer 124 Suppl 7:1583-1589
Jerant, Anthony; Fenton, Joshua J; Kravitz, Richard L et al. (2018) Association of Clinician Denial of Patient Requests With Patient Satisfaction. JAMA Intern Med 178:85-91
Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2018) A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol 180:445-448
Besprozvannaya, Marina; Dickson, Eamonn; Li, Hao et al. (2018) GRAM domain proteins specialize functionally distinct ER-PM contact sites in human cells. Elife 7:
Turner, David C; Kondic, Anna G; Anderson, Keaven M et al. (2018) Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clin Cancer Res 24:5841-5849
Matsumoto, Collin; Jiang, Yan; Emathinger, Jacqueline et al. (2018) Short Telomeres Induce p53 and Autophagy and Modulate Age-Associated Changes in Cardiac Progenitor Cell Fate. Stem Cells 36:868-880

Showing the most recent 10 out of 836 publications